2021
Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support
Crothers K, DeFaccio R, Tate J, Alba PR, Goetz MB, Jones B, King JT, Marconi V, Ohl ME, Rentsch CT, Rodriguez-Barradas MC, Shahrir S, Justice AC, Akgün KM, Group F. Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support. European Respiratory Journal 2021, 60: 2102532. PMID: 34824060, PMCID: PMC8841623, DOI: 10.1183/13993003.02532-2021.Peer-Reviewed Original ResearchConceptsIntensive respiratory supportHospitalised COVID-19 patientsCOVID-19 patientsNasal cannulaEarly dexamethasoneRespiratory supportSevere acute respiratory syndrome coronavirus 2Low-flow nasal cannulaAcute respiratory syndrome coronavirus 2Coronavirus disease 2019 (COVID-19) patientsRespiratory syndrome coronavirus 2Cox proportional hazards modelUS Veterans Affairs hospitalsSyndrome coronavirus 2Veterans Affairs hospitalProportional hazards modelCOVID-19Prior corticosteroidsCause mortalityMortality benefitTotal patientsCoronavirus 2Unexposed groupReal-world findingsEarly initiationAssociation between living with children and outcomes from covid-19: OpenSAFELY cohort study of 12 million adults in England
Forbes H, Morton CE, Bacon S, McDonald HI, Minassian C, Brown JP, Rentsch CT, Mathur R, Schultze A, DeVito NJ, MacKenna B, Hulme WJ, Croker R, Walker AJ, Williamson EJ, Bates C, Mehrkar A, Curtis HJ, Evans D, Wing K, Inglesby P, Drysdale H, Wong AYS, Cockburn J, McManus R, Parry J, Hester F, Harper S, Douglas IJ, Smeeth L, Evans SJW, Bhaskaran K, Eggo RM, Goldacre B, Tomlinson LA. Association between living with children and outcomes from covid-19: OpenSAFELY cohort study of 12 million adults in England. The BMJ 2021, 372: n628. PMID: 33737413, PMCID: PMC7970340, DOI: 10.1136/bmj.n628.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionIntensive care admissionHospital admissionCare admissionCohort studyCOVID-19Covid-19 related hospital admissionSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Wave 2Primary care dataRelated hospital admissionsSyndrome coronavirus 2Adults 65 yearsCohort of adultsCOVID-19 outcomesCoronavirus disease 2019COVID-19 mortalityRisk of infectionWave 1UK pandemicHazard ratioIntensive careAbsolute risk
2020
Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform
Rentsch CT, DeVito NJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, Schultze A, Hulme WJ, Croker R, Walker AJ, Williamson EJ, Bates C, Bacon S, Mehrkar A, Curtis HJ, Evans D, Wing K, Inglesby P, Mathur R, Drysdale H, Wong AYS, McDonald HI, Cockburn J, Forbes H, Parry J, Hester F, Harper S, Smeeth L, Douglas IJ, Dixon WG, Evans SJW, Tomlinson L, Goldacre B. Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. The Lancet Rheumatology 2020, 3: e19-e27. PMID: 33349815, PMCID: PMC7745258, DOI: 10.1016/s2665-9913(20)30378-7.Peer-Reviewed Original ResearchCOVID-19 mortalitySystemic lupus erythematosusPopulation-based cohort studyLupus erythematosusRheumatoid arthritisOpenSAFELY platformCohort studyImmunosuppressive drugsRheumatological diseasesSevere acute respiratory syndrome coronavirus 2National primary care dataAcute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Effectiveness of hydroxychloroquinePre-exposure usePrimary care dataSyndrome coronavirus 2COVID-19 outbreakCumulative COVID-19 mortalityCOVID-19Medical Research CouncilNegative control outcomesCOVID-19 deathsHydroxychloroquine useCox regressionRisk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform
Schultze A, Walker AJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, Rentsch CT, Williamson E, Drysdale H, Croker R, Bacon S, Hulme W, Bates C, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, Tomlinson L, Mathur R, Wing K, Wong AYS, Forbes H, Parry J, Hester F, Harper S, Evans SJW, Quint J, Smeeth L, Douglas IJ, Goldacre B, Collaborative O. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. The Lancet Respiratory Medicine 2020, 8: 1106-1120. PMID: 32979987, PMCID: PMC7515601, DOI: 10.1016/s2213-2600(20)30415-x.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, InhalationAdolescentAdrenal Cortex HormonesAdultAgedAged, 80 and overAsthmaBetacoronavirusCohort StudiesCoronavirus InfectionsCOVID-19Electronic Health RecordsEnglandFemaleHumansMaleMiddle AgedMuscarinic AntagonistsPandemicsPneumonia, ViralProportional Hazards ModelsPulmonary Disease, Chronic ObstructiveRegression AnalysisSARS-CoV-2Young AdultConceptsChronic obstructive pulmonary diseaseCOVID-19-related deathsIndex dateObstructive pulmonary diseaseElectronic health recordsOpenSAFELY platformRespiratory medicationsCOPD cohortHazard ratioPulmonary diseaseAsthma cohortPrimary care electronic health recordsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2High-dose ICSHigh-dose ICSsRegular ICS useΒ-agonistsObservational cohort studyUK Medical Research CouncilRisk of deathCox regression modelAcute respiratory diseaseSyndrome coronavirus 2